ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
56 announcements with these filters
Astec LifeSciences Limited successfully redeemed its listed Commercial Paper worth ₹25 Crore on maturity. The timely payment reinforces the company's financial discipline and debt servicing reliability.
Astec LifeSciences clarified to NSE that recent volume spurts are market-driven with no undisclosed developments. The company maintains full compliance with all SEBI disclosure regulations.
Astec LifeSciences submitted its Annual Secretarial Compliance Report for the financial year ended March 2026. The report details regulatory compliance status and past governance observations.
Astec LifeSciences Limited confirmed the timely redemption of ₹25 Crore worth of Commercial Papers. The payment was made upon maturity on May 22, 2026.
Astec LifeSciences notified shareholders regarding the mandatory transfer of unclaimed dividends and shares to the IEPF. This routine regulatory compliance follows the seven-year non-claim threshold.
Astec LifeSciences fixed June 2026 record dates for redeeming four Commercial Paper series. Investors should track these dates to ensure timely receipt of maturity payments.
Astec LifeSciences Limited has approved the grant of 1,142 stock options to an eligible grantee under its ESOP 2012 plan. The options have an exercise price of Rs.10 each and will vest over a three-year period. This move aligns employee interests with long-term shareholder value creation.
Astec LifeSciences Limited confirmed the timely redemption and payment of ₹25 Crore for its Commercial Papers (Series ASTEC-CP-186). The papers matured on April 29, 2026. This announcement demonstrates the company's adherence to its debt obligations and financial stability.
Astec LifeSciences Limited has fixed the record dates for the redemption of two Commercial Paper series maturing in May 2026. The total redemption amount is ₹50 Crore, split across two ₹25 Crore tranches listed on the NSE.
Astec LifeSciences Limited issued a compliance certificate for its 8.90% Unsecured Non-Convertible Debentures totalling ₹49 Crore. As the NCDs are unsecured, the company filed a nil security cover certificate for the quarter ended March 31, 2026.
Astec LifeSciences Limited confirmed the full utilization of ₹49 Crore raised through Private Placement of Non-Convertible Debentures. The company reported no deviations or variations in the use of proceeds for the quarter ended March 31, 2026.
Astec LifeSciences reported a 17.1% year-on-year increase in FY26 consolidated total income to ₹453.2 Crore. Despite a loss after tax of ₹80.9 Crore, the company achieved EBITDA breakeven at ₹0.5 Crore. Growth was primarily driven by improved volumes in the Enterprise and CDMO segments.
Astec Lifesciences Ltd reported revenue from operations of ₹158.6 Cr (+32.7% YoY) and a net loss of ₹7.5 Cr for Q4 FY26.
Astec LifeSciences Limited reported its audited financial results for the quarter and year ended March 31, 2026. The Board also approved the appointment of new directors including Mr. Vishal Sharma and Mr. Burjis Godrej as Non-Executive Directors, and fixed July 31, 2026, as the date for its 32nd Annual General Meeting.
Astec LifeSciences Limited submitted its annual disclosure for the centralized database of corporate bonds as of March 31, 2026. The filing confirms listing details and interest payment status for its ₹49 Crore Non-Convertible Debentures (ISIN: INE563J08023). ICRA reaffirmed the credit rating at [ICRA]AA- with a negative outlook.
Astec LifeSciences Limited clarified to NSE that there are no undisclosed price-sensitive developments or events requiring disclosure under SEBI regulations. The company confirmed compliance with all listing and insider trading regulations, stating that recent share price movements are market-driven and not linked to any internal corporate actions.
Astec LifeSciences Ltd clarified to BSE that there are no undisclosed price-sensitive developments or events requiring disclosure under SEBI regulations. The company confirmed compliance with all listing and insider trading regulations. This response follows a clarification sought by the exchange regarding recent share price movement.
Astec LifeSciences Limited has scheduled a Board Meeting for Monday, April 27, 2026. The board will consider and approve the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026.
Astec LifeSciences Limited has scheduled a Board Meeting for April 27, 2026. The Board will consider and approve the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026.
Astec LifeSciences Limited successfully redeemed its Commercial Paper (Series Astec-CP-188) by making a timely payment of ₹25 Crore on April 15, 2026. The instrument, originally issued in November 2025, was listed on the NSE.
Astec LifeSciences Limited announced a major management shuffle effective April 13, 2026. Nadir Godrej will retire, while Vishal Sharma is appointed as CEO (Chemicals). Burjis Godrej transitions to a Non-Executive Director role. Additionally, Mathew Eipe joins as an Independent Director and Arijit Mukherjee is appointed to the Board, strengthening leadership across the Godrej Industries Group.
Astec LifeSciences announced major leadership changes: Mr. Nadir Godrej retired as Chairman, succeeded by Mr. Vishal Sharma. Mr. Burjis N. Godrej stepped down as Managing Director to become a Non-Executive Director, while Mr. Arijit Mukherjee was appointed Executive Director and COO. These strategic board transitions are effective from April 13, 2026.
Astec LifeSciences announced major leadership changes: Mr. Nadir Godrej retired as Chairperson, replaced by Mr. Vishal Sharma. Mr. Burjis Godrej resigned as Managing Director to move to the parent company, remaining as a Non-Executive Director. Additionally, Mr. Mathew Eipe and Mr. Arijit Mukherjee were appointed to the Board, with the latter as COO for a three-year term.
Astec LifeSciences Limited certified that it did not issue any fresh Commercial Paper (CP) during the quarter ended March 31, 2026. This filing is a regulatory compliance confirmation regarding the utilization and status of issue proceeds under SEBI regulations.
Astec LifeSciences Limited reported the status of its private placement debt securities for the half-year ended March 31, 2026. The company has ₹49 Crore outstanding in 8.90% Non-Convertible Debentures (ISIN: INE563J08023) maturing in March 2027. This filing is a routine regulatory disclosure under SEBI's master circular for debt securities.
Astec Lifesciences Ltd reported a net loss of ₹15.7 Cr for Q3 FY26.